"In China, breast cancer ranks first in the incidence rate of female malignant tumors, with 420000 new cases in 2020. With the development of society, the incidence rate of breast cancer in China is becoming younger. According to a previous statistics from Sun Yat sen University, the peak age of female breast cancer in China is 45 to 55 years old, which is about 10 years younger than that in foreign countries." Professor Wang Shusen, chief expert of breast cancer internal medicine and director of internal medicine breast disease area of Sun Yat sen University Cancer Center, said, As the incidence rate continues to rise, breast cancer prevention and screening work is crucial, and drug access needs to be further improved. At the age of 45, 41, 35, 24... in the Cancer Center of Sun Yat sen University, many young breast cancer patients are diagnosed every day. The annual growth rate of incidence rate of breast cancer in China is twice the world average, and premenopausal patients accounted for about 60% at the time of initial diagnosis. "The cause of breast cancer is multifaceted, which may be related to heredity, and the influence of bad lifestyle cannot be ruled out." Wang Shusen said that the breast is a superficial organ in vitro, which is easy to be found early through the patient's own palpation, which is different from colon cancer and lung cancer. For most patients with early breast cancer, if the treatment is timely, the 5-year survival rate can reach more than 90%. The earlier the discovery, the better the treatment effect, and the higher the likelihood of the patient being cured, "Wang Shusen reminds women to have a screening awareness and try to achieve early detection, diagnosis, and treatment as much as possible. Women over the age of 40 can undergo molybdenum targets once every one to two years, and B-ultrasound can be performed once every six months to a year. Some high-risk individuals even need to start regular screening before the age of 35. In Wang Shusen's view, the biggest progress in the field of breast cancer in the past 20 years was in drug treatment. New drugs were constantly emerging. Targeted drugs, including CDK4/6 inhibitors, also began to enter clinical application, greatly improving the survival period of patients. In addition, facing different age groups, drug development is also making efforts. Previous clinical studies have often focused on postmenopausal breast cancer patients, and specific drugs are also mainly targeted at this age group. However, in recent years, there have been more and more studies focusing on premenopausal breast cancer patients. The MONALEESA series of studies around the CDK4/6 inhibitor Rebosili, which was approved for marketing this year, include MONALEESA-7 studies focusing on premenopausal patients. In addition, it needs special attention that about 10% -15% of HR+/HER2- patients with breast cancer have visceral crisis status. Visceral crisis in patients with breast cancer usually refers to the fact that the symptoms of the patients can not make them maintain normal life, including lung metastasis or liver metastasis. For patients diagnosed with visceral crisis, endocrine therapy cannot solve the more urgent symptoms, which can affect the patient's survival time; All major guidelines recommend chemotherapy for advanced breast cancer with rapid disease progression or highly symptomatic disease and life-threatening visceral crisis, but the research of chemotherapy in such patients is still blank, and the side effects are large. Therefore, patients with visceral crisis of breast cancer urgently need targeted treatment strategies with rapid effect and low side effects. In 2022, Right Ch